Zymeworks Beats on EPS, Posts $512.92M Revenue vs $227.40M Estimate

Zymeworks (NASDAQ: ZYME) reported quarterly EPS of $2.28 on Monday, beating the consensus estimate of $2.27 by $0.01. The far larger surprise sat in the top line: revenue reached $512.92 million against analyst expectations of $227.40 million, according to FiscalAI. For finance teams tracking clinical-stage biotech, the gap between a marginal earnings beat and a revenue figure more than double the estimate is the story worth unpacking.

The profitability picture remains deeply negative. Zymeworks posted a net margin of negative 405.31% and a return on equity (net income divided by shareholder equity) of negative 72.30%. In practical terms, the company is still spending several multiples of what it collects — a structure common among developers of engineered medicines that have not yet scaled commercial sales.

How did the market respond?

The stock climbed $1.18 during Monday's session to $30.81. Trading volume ran at 1,108,276 shares against an average of 779,299 — roughly 42% above the norm, a signal of genuine repositioning rather than routine churn.

The valuation context:

• Market capitalization: $2.17 billion
• Twelve-month range: $16.57 to $31.49, leaving the stock just below its high
• Fifty-day simple moving average: $27.40; 200-day average: $25.34 (the short average sitting above the long one indicates a sustained upward trend)
• P/E ratio of negative 15.25, consistent with reported losses
• Beta of 1.32, meaning the stock moves about 32% more than the overall market

What does the insider selling signal?

EVP Adam Schayowitz sold 13,832 shares on Friday, October 9th, at an average price of $25.85, for a total of $357,557.20, according to an SEC filing. The transaction cut his stake by 37.35%; he now holds 23,205 shares valued at approximately $599,849.25.

Practitioners should note the stated purpose: the sale covered tax withholding obligations tied to the vesting of equity awards. That mechanical driver carries a different read than discretionary selling. Insiders still own 37.73% of the company's stock — an unusually high figure that concentrates alignment, and risk, inside the organization.

Where do analysts see the stock going?

Brokerages have moved targets upward across recent notes:

• Deutsche Bank set a $32.00 price target on Wednesday, August 26th
• HC Wainwright raised its objective from $51.00 to $55.00 with a Buy rating, also August 26th
• Stifel Nicolaus set a $46.00 objective on Friday, August 7th
• B. Riley Financial reiterated a Buy and lifted its target from $40.00 to $44.00 on Monday, August 10th
• Wolfe Research initiated coverage on Thursday, September 17th, with an Outperform rating

The aggregate picture: twelve Buy ratings, one Hold and one Sell, producing an average rating of Moderate Buy and a consensus price target of $41.67, per MarketBeat data. That target stands roughly 35% above Monday's close — even after the earnings-driven rally.

What sits behind the numbers?

Zymeworks, headquartered in Vancouver, Canada, develops engineered medicines focused on cancer and other serious diseases. Its antibody-engineering platform builds therapies that engage multiple biological targets or modify immune responses.

The lead program is zanidatamab, a HER2-targeted bispecific antibody (an antibody designed to bind two disease targets simultaneously). In the United States, partner Jazz Pharmaceuticals markets it as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

For CFOs and finance leaders, the takeaway is a familiar biotech pattern: a partnered commercial asset generating revenue above model, losses that remain structurally large, and an insider-heavy register where equity-award mechanics, not sentiment, explain most trading by executives.